u/MortiferaJ

Context: There are seven peptides on the FDA's Pharmacy Compounding Advisory Committee (PCAC) agenda for July 23-24: BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, Epitalon. A yes vote at this meeting adds a compound to the Category 1 Approved 503A Bulks List (legal pharmacy compounding with a prescription, not general FDA drug approval, not insurance coverage. not over-the-counter availability)

Background most coverage skips at the moment:

1. PCAC has never approved a peptide. Across 15 years and roughly 12 peptide-class ballots it has cast one yes (Glutathione, 2022, a tripeptide antioxidant in a different clinical lane). The 2024 committee voted no on CJC-1295, Ipamorelin, Thymosin alpha-1, and AOD-9604. The July committee has four confirmed seats and six temporary appointees still to be named.

2. The panel isn't voting on whether peptides become legal. It's voting on which specific uses become legal.

• BPC-157 for ulcerative colitis (not tendons, recovery, gut lining)
• TB-500 for wound healing (not injury recovery)
• KPV for wound healing and inflammatory (broad match to community use)
• MOTS-C for obesity and osteoporosis (not cognition or metabolic optimization broadly)
• DSIP for insomnia (matches community use)
• Semax for migraine (not cognition, ADHD, focus)
• Epitalon for insomnia (not anti-aging, longevity)

Even a yes vote for BPC-157 doesn't legalize tendon use. It legalizes UC use. Off-label prescribing exists but pharmacies/prescribers will normally to stay within the specific reviewed usecases under 503A (the usecases the PCAC are voting on).

3. Pricing. Neither path stays at today's prices after a yes vote. Legal compounded versions typically run 3x to 10x gray-market costs (pharma-grade API, sterile manufacturing, professional dispensing). The gray market doesn't stay cheap either. FDA enforcement on uncovered uses tends to intensify after a PCAC vote, with vendor exits, import risk, and supply disruption pushing research-chemical prices up. Whichever route you take, expect higher costs than today.

4. Public comment. Docket FDA-2025-N-6895 is open through July 22. Comments by July 9 reach the committee. The 2022 Glutathione yes drew 8,152 docket comments. The 2024 peptide dockets drew 13 total.

Here is my full analysis with per-compound info, the roster breakdown, and the pricing methodology: https://feelpep.co/journal/what-the-peptide-panel-is-really-voting-on